Stockscreener 앱 받기
0.0101
4.72%
-0.0005
시간 외 거래:
.01
-0.000100
-0.99%
전일 마감가:
$0.0106
열려 있는:
$0.013
하루 거래량:
1.55M
Relative Volume:
30.13
시가총액:
$N/A
수익:
-
순이익/손실:
$-20.70M
주가수익비율:
-0.000138
EPS:
-73.3042
순현금흐름:
$-14.40M
1주 성능:
-4.72%
1개월 성능:
-98.11%
6개월 성능:
-99.97%
1년 성능:
-100.00%
1일 변동 폭
$0.0099
$0.013
1주일 범위
$0.0099
$0.013
52주 변동 폭
$0.0099
$0.013
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Compare CERO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
0.0101 | 0 | 0 | -20.70M | -14.40M | -73.30 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cero Therapeutics Holdings Inc Stock (CERO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-23 | 업그레이드 | D. Boral Capital | Hold → Buy |
Cero Therapeutics Holdings Inc 주식(CERO)의 최신 뉴스
CERo Therapeutics Holdings Announces Clinical Update From CERTAIN-T Phase 1 CER-1236 Trial - marketscreener.com
CERo Therapeutics Announces Clinical Update from CERTAIN-T - GlobeNewswire
CERo Therapeutics Raises Funding via Convertible Note Financing - TipRanks
CERO (OTCQB: CERO) registers 729.6M shares as conversion resale coverage - Stock Titan
CERo Therapeutics Secures $750,000 10% Convertible Note With SRX Health Solutions, Due 2027 - TradingView
CERO Therapeutics (CERO) issues $750K 10% convertible note with 4.99% cap - Stock Titan
CERo Therapeutics Holdings, Inc. announced that it has received $0.75 million in funding from SRx Health Solutions Inc. - marketscreener.com
CEROW | CERO THERAPEUTICS WTS 29 Insider Trading - Quiver Quantitative
Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - MSN
CERo Therapeutics (OTCQB: CERO) registers 729.6M common shares; 10-Q updates show cash, loss - Stock Titan
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CERo Therapeutics (OTCQB: CERO) warns of going-concern risk - Stock Titan
TradingKey - TradingKey
CERo completes second cohort dosing in phase 1 trial - Investing.com UK
CERo completes second cohort dosing in phase 1 trial By Investing.com - Investing.com Nigeria
Experimental CAR-T for blood cancers moves to higher dose - Stock Titan
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial - GlobeNewswire
MSN Money - MSN
CERo Therapeutics Raises Capital via Convertible Note Financing - TipRanks
CERo Therapeutics Raises $400,000 via 10% Convertible Note From Keystone, Up to $1M - TradingView
[424B3] CERO THERAPEUTICS HOLDINGS, INC. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
[8-K] CERO THERAPEUTICS HOLDINGS, INC. Reports Material Event - Stock Titan
CERo Therapeutics (CERO) registers 729.6M common shares in S-1 supplement - Stock Titan
Insider ownership and executive pay at CERo Therapeutics (NASDAQ: CERO) - Stock Titan
Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone - MSN
CERo Therapeutics Holdings, Inc. announced that it has received $0.4 million in funding from Keystone Capital Partners LLC - marketscreener.com
CERO Therapeutics (CERO) director receives stock options for 1.82M shares - Stock Titan
CERO Therapeutics (CERO) director files Form 3 ownership - Stock Titan
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial - ADVFN
CERO SEC FilingsCERo Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
CERo Therapeutics: Advancing Next-Generation Engineered T Cell Immunotherapy for Cancer Treatment - Minichart
729.6M-share registration — CERo Therapeutics Holdings (OTCQB: CERO) - Stock Titan
CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CERo Therapeutics Secures Convertible Note Financing Facility - TipRanks
CERO Therapeutics (CERO) adds up to $1M via new convertible note - Stock Titan
CERo expands blood cancer trial after sixth patient dose - Stock Titan
Aug Weekly: Is CERo Therapeutics Holdings Inc exposed to currency risks2026 Reactions & Stock Market Timing Techniques - baoquankhu1.vn
Chipmakers Recap: Is CERo Therapeutics Holdings Inc Equity Warrant stock showing strong momentumWeekly Gains Report & Verified Entry Point Detection - baoquankhu1.vn
Trend Recap: What is CERo Therapeutics Holdings Inc Equity Warrants valuation compared to sectorTrade Volume Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial - ADVFN
US Stocks Recap: Can Fifth Era Acquisition Corp I sustain its profitabilityQuarterly Profit Report & AI Based Trade Execution Alerts - baoquankhu1.vn
EV Market: Can CERo Therapeutics Holdings Inc be recession proofSwing Trade & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug PreEarnings: What is CERo Therapeutics Holdings Inc Equity Warrants revenue forecast2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
CERo Therapeutics Holdings, Inc. announced that it has received $0.35 million in funding - marketscreener.com
Quarterly Trades: What is CERo Therapeutics Holdings Inc Equity Warrants revenue forecast2026 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn
Insider Buy: Is CGEM subject to activist investor interestWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Update: Is CERo Therapeutics Holdings Inc Equity Warrant benefiting from interest rate changes2026 Closing Moves & Weekly High Return Stock Opportunities - baoquankhu1.vn
CERo Therapeutics Delays 2025 Annual Report Filing - TipRanks
CERo Therapeutics (NASDAQ: CERO) delays 2025 10-K; preliminary $19.9M loss - Stock Titan
History Review: What is CERo Therapeutics Holdings Inc Equity Warrants valuation compared to sector - baoquankhu1.vn
Can CERo Therapeutics Holdings Inc. deliver consistent dividends2026 Levels & Reliable Intraday Trade Plans - baoquankhu1.vn
Cero Therapeutics Holdings Inc (CERO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):